Soligenix Inc (SNGX)

Currency in USD
1.2900
-0.1000(-7.19%)
Real-time Data·
SNGX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
SNGX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.28001.4050
52 wk Range
1.09005.4000
Key Statistics
Prev. Close
1.39
Open
1.4
Day's Range
1.28-1.405
52 wk Range
1.09-5.4
Volume
196.92K
Average Volume (3m)
908.24K
1-Year Change
-70.8%
Book Value / Share
1.14
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SNGX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.5000
Upside
+1,489.15%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Soligenix Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Soligenix Inc Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet’s disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Compare SNGX to Peers and Sector

Metrics to compare
SNGX
Peers
Sector
Relationship
P/E Ratio
−0.4x−12.2x−0.5x
PEG Ratio
−0.01−0.060.00
Price/Book
1.2x1.2x2.6x
Price / LTM Sales
1,805.0x6.2x3.2x
Upside (Analyst Target)
-71.8%40.5%
Fair Value Upside
Unlock26.9%4.4%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 20.5000
(+1,489.15% Upside)

Earnings

Latest Release
May 09, 2025
EPS / Forecast
-1.06 / -0.11
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SNGX Income Statement

People Also Watch

2.68
INMB
-3.72%
0.993
WINT
-2.62%
1.22
KLTO
-3.89%
11.959
NUWE
-8.01%
2.150
VOR
-0.92%

FAQ

What Stock Exchange Does Soligenix Inc Trade On?

Soligenix Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Soligenix Inc?

The stock symbol for Soligenix Inc is "SNGX."

What Is the Soligenix Inc Market Cap?

As of today, Soligenix Inc market cap is 4.21M.

What Is Soligenix Inc's Earnings Per Share (TTM)?

The Soligenix Inc EPS (TTM) is -4.25.

From a Technical Analysis Perspective, Is SNGX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Soligenix Inc Stock Split?

Soligenix Inc has split 5 times.

How Many Employees Does Soligenix Inc Have?

Soligenix Inc has 15 employees.

What is the current trading status of Soligenix Inc (SNGX)?

As of 25 Jul 2025, Soligenix Inc (SNGX) is trading at a price of 1.29, with a previous close of 1.39. The stock has fluctuated within a day range of 1.28 to 1.41, while its 52-week range spans from 1.09 to 5.40.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.